Evidence map›Paper›PMID 27017514›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2016

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.

Licette C Y Liu, Adriaan A Voors, John R Teerlink, Gad Cotter, Beth A Davison, G Michael Felker, Gerasimos Filippatos, Yakuan Chen, Barry H Greenberg, Piotr Ponikowski and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Trial
  5. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Trial
  6. Trial
  7. Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Article
  8. Review
  9. Review
  10. Heart Disease and Relaxin: New Actions for an Old Hormone.Trends in endocrinology and metabolism: TEM · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 6 countries.

Licette C Y LiuDepartment of Cardiology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Adriaan A VoorsDepartment of Cardiology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. a.a.voors@umcg.nl.
John R TeerlinkSan Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA.
Gad CotterMomentum Research, Durham, NC, USA.
Beth A DavisonMomentum Research, Durham, NC, USA.
G Michael FelkerDuke University School of Medicine, Duke Heart Center, Durham, NC, USA.
Gerasimos FilippatosSchool of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Yakuan ChenColumbia University Medical Center, New York, NY, USA.
Barry H GreenbergUniversity of California at San Diego, San Diego, CA, USA.
Piotr PonikowskiClinical Military Hospital, Medical University, Wroclaw, Poland.
Peter S PangIndiana University School of Medicine, Indianapolis, IN, USA.
Margaret F PrescottNovartis Pharma, Basel, Switzerland.
Tsushung A HuaNovartis Pharma, Basel, Switzerland.
Thomas M SeverinNovartis Pharma, Basel, Switzerland.
Marco MetraUniversity of Brescia, Brescia, Italy.
Novartis (Switzerland) · CHMomentum Research · USUniversity Medical Center Groningen · NLColumbia University Irving Medical Center · USDuke University · USIndiana University School of MedicineNational and Kapodistrian University of Athens · GRUniversity of Brescia · ITUniversity of California, San Diego · USUniversity of California, San Francisco · USWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerelaxin showed beneficial effects on clinical outcome and trajectories of renal markers in patients with acute heart failure. We aimed to study the interaction between renal function and the treatment effect of serelaxin.

methodsIn the current post hoc analysis of the RELAX-AHF trial, we included all patients with available estimated glomerular filtration rate (eGFR) at baseline (n = 1132). Renal impairment was defined as an eGFR <60 ml/min/1.73 m(2) estimated by creatinine.

results817 (72.2 %) patients had a baseline eGFR <60 ml/min/1.73 m(2). In placebo-treated patients, baseline renal impairment was related to a higher 180 day cardiovascular (HR 3.12, 95 % CI 1.33-7.30) and all-cause mortality (HR 2.81, 95 % CI 1.34-5.89). However, in serelaxin-treated patients, the risk of cardiovascular and all-cause mortality was less pronounced (HR 1.19, 95 % CI 0.54 -2.64; p for interaction = 0.106, and HR 1.15 95 % CI 0.56-2.34 respectively; p for interaction = 0.088). In patients with renal impairment, treatment with serelaxin resulted in a more pronounced all-cause mortality reduction (HR 0.53, 95 % CI 0.34-0.83), compared with patients without renal impairment (HR 1.30, 95 % CI 0.51-3.29).

conclusionRenal dysfunction was associated with higher cardiovascular and all-cause mortality in placebo-treated patients, but not in serelaxin-treated patients. The observed reduction in (cardiovascular) mortality in RELAX-AHF was more pronounced in patients with renal dysfunction. These observations need to be confirmed in the ongoing RELAX-AHF-2 trial.

Indexed as

Acute DiseaseAgedAged, 80 and overCardiovascular AgentsFemaleGlomerular Filtration RateHeart FailureHumansKaplan-Meier EstimateKidneyKidney DiseasesMaleMiddle AgedRandomized Controlled Trials as TopicRecombinant ProteinsRelaxinCardiovascular AgentsRecombinant ProteinsRelaxinserelaxin protein, humanAcute heart failureNumber needed to treatRenal functionRenal impairmentSerelaxin

Identifiers

PMID27017514
PMCPMC4988995
OpenAlexW2311933341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.